| Title |
Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature
|
|---|---|
| Published in |
BMC Pharmacology and Toxicology, May 2013
|
| DOI | 10.1186/2050-6511-14-27 |
| Pubmed ID | |
| Authors |
Maria AP Martins, Adriano MM Reis, Mariana F Sales, Vandack Nobre, Daniel D Ribeiro, Manoel OC Rocha, Antônio LP Ribeiro |
| Abstract |
Rifampicin remains one of the first-line drugs used in tuberculosis therapy. This drug's potential to induce the hepatic cytochrome P450 oxidative enzyme system increases the risk of drug-drug interactions. Thus, although the presence of comorbidities typically necessitates the use of multiple drugs, the co-administration of rifampicin and warfarin may lead to adverse drug events. We report a bleeding episode after termination of the co-administration of rifampicin and warfarin and detail the challenges related to international normalized ratio (INR) monitoring. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 20% |
| United Kingdom | 1 | 20% |
| Canada | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Slovenia | 1 | 1% |
| Switzerland | 1 | 1% |
| Unknown | 76 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 15% |
| Student > Postgraduate | 11 | 14% |
| Student > Bachelor | 11 | 14% |
| Student > Ph. D. Student | 7 | 9% |
| Student > Master | 7 | 9% |
| Other | 14 | 18% |
| Unknown | 17 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 14% |
| Nursing and Health Professions | 4 | 5% |
| Agricultural and Biological Sciences | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Other | 5 | 6% |
| Unknown | 20 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2021.
All research outputs
#2,101,898
of 23,911,072 outputs
Outputs from BMC Pharmacology and Toxicology
#29
of 462 outputs
Outputs of similar age
#17,678
of 195,245 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#1
of 11 outputs
Altmetric has tracked 23,911,072 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 462 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,245 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.